Comparative Pharmacology
Head-to-head clinical analysis: CLARITIN HIVES RELIEF REDITAB versus FEXOFENADINE HYDROCHLORIDE ALLERGY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLARITIN HIVES RELIEF REDITAB versus FEXOFENADINE HYDROCHLORIDE ALLERGY.
CLARITIN HIVES RELIEF REDITAB vs FEXOFENADINE HYDROCHLORIDE ALLERGY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inverse agonist of peripheral histamine H1 receptors, inhibiting histamine release from mast cells and basophils.
Fexofenadine is a selective peripheral H1-receptor antagonist that inhibits histamine release from mast cells and basophils.
10 mg orally once daily
60 mg orally twice daily or 180 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life of loratadine is 8.4 hours (range 3–20 hours); for its active metabolite descarboethoxyloratadine, it is 24.9 hours (range 8.8–45 hours). Clinical context: Steady-state concentrations are achieved by day 5.
Terminal elimination half-life is 14.4 hours in healthy adults. In renal impairment, half-life may be prolonged up to 59 hours.
Primarily renal (approximately 40% as metabolites, <1% as unchanged drug) and fecal (approximately 40% as metabolites).
Primarily excreted unchanged in feces (80%) and urine (11%). Biliary excretion contributes to fecal elimination.
Category C
Category A/B
Antihistamine
Antihistamine